All In Biotech

Drug Trial Radar · NCT04961528

ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

315

Actual

Start

Mar 27, 2022

Primary completion

Dec 28, 2025

Study completion Mar 25, 2026

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France
First posted
Jul 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims is to verify the hypothetize that inhaled Tranexamic Acid (TXA) or Terlipressin (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. This randomized double-blind multicenter triple arm trial compares the administration of TXA to TER to placebo in patients with mild to severe hemoptysis.

Conditions

  • Hemoptysis

Interventions

  • Tranexamic Acid 500 MGDrug

    Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days

  • TerlipressinDrug

    Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days

  • PlaceboDrug

    Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with complete or partial resolution of hemoptysis without the use of any interventional procedure.Time frame: 3 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • AP-HP, Hôpital Européen Georges Pompidou

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.